In a recent series of 102 non-small-cell lung cancer patients, high levels of BRCA1 mRNA were associated with better response and decreased risk of progression to gemcitabine plus docetaxel [37]. The gene discussed is BRCA1; the disease is non-small cell lung carcinoma.